Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

COMET-ICE, 2021
 
NCT04545060
RCTsotrovimab (Xevudy; VIR-7831)placeboCOVID 19 outpatientslow
528/529 conclusif
  • demonstrated 79 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
  • suggested 76 % decrease in clinical deterioration with a high degree of certainty due to low risk of bias
  • suggested 80 % decrease in hospitalization with a high degree of certainty due to low risk of bias
Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalisation and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease (press release)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).